Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a
ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a
different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be
enrolled in 3 clinical sites.